References: Pharmacological therapy for cognitive impairment in dementia

Birks JS, Chong LY, Grimley Evans J. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2015;9:CD001191. https://www.ncbi.nlm.nih.gov/pubmed/26393402
Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2018;6:CD001190. https://www.ncbi.nlm.nih.gov/pubmed/29923184
Birks J, McGuinness B, Craig D. Rivastigmine for vascular cognitive impairment. Cochrane Database Syst Rev 2013;(5):CD004744. https://www.ncbi.nlm.nih.gov/pubmed/23728651
Buckley JS, Salpeter SR. A risk-benefit assessment of dementia medications: Systematic review of the evidence. Drugs Aging 2015;32(6):453–67. https://www.ncbi.nlm.nih.gov/pubmed/25941104
Fink HA, Linskens EJ, MacDonald R, Silverman PC, McCarten JR, Talley KMC, et al. Benefits and harms of prescription drugs and supplements for treatment of clinical Alzheimer-type dementia. Ann Intern Med 2020;172(10):656–68. https://www.ncbi.nlm.nih.gov/pubmed/32340037
Guideline Adaption Committee. Clinical practice guidelines and principles of care for people with dementia. Sydney: Guideline Adaption Committee; 2016. http://sydney.edu.au/medicine/cdpc/resources/dementia-guidelines.php
Janssen-Cilag Pty Ltd. Reminyl: galantamine modified release capsule Australian product information. Canberra: Therapeutic Goods Administration (TGA); 2010 (review 2020). https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-04279-3&d=202005051016933
Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, et al. Dementia prevention, intervention, and care. Lancet 2017;390(10113):2673–734. https://www.ncbi.nlm.nih.gov/pubmed/28735855
Lundbeck Australia Pty Ltd. Ebixa (memantine hydrochloride) film-coated tablets Australian product information. Canberra: Therapeutic Goods Administration (TGA); 2003 (review 2020). https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-05639-3&d=201905081016933
Massoud F, Desmarais JE, Gauthier S. Switching cholinesterase inhibitors in older adults with dementia. Int Psychogeriatr 2011;23(3):372–8. https://www.ncbi.nlm.nih.gov/pubmed/21044399
McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 2017;89(1):88–100. https://www.ncbi.nlm.nih.gov/pubmed/28592453
McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE, et al. Memantine for dementia. Cochrane Database Syst Rev 2019;3:CD003154. https://www.ncbi.nlm.nih.gov/pubmed/30891742
Micca JL, Galvin JE, Velting DM, Meng X. Efficacy of 13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch on activities of daily living in severe Alzheimer's disease. SAGE Open Med 2014;2:2050312114561569. https://www.ncbi.nlm.nih.gov/pubmed/26770753
National Institute for Health and Care Excellence (NICE). Dementia: assessment, management and support for people living with dementia and their carers (NG97). London: NICE; 2018. https://www.nice.org.uk/guidance/ng97
Novartis Pharmaceuticals Australia Pty Ltd. Exelon patch (rivastigmine) Australian product information. Canberra: Therapeutic Goods Administration (TGA); 2008 (review 2019). https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-03173-3&d=20191114101693
O’Brien JT, Holmes C, Jones M, Jones R, Livingston G, McKeith I, et al. Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol 2017;31(2):147–68. https://www.ncbi.nlm.nih.gov/pubmed/28103749
Reeve E, Farrell B, Thompson W, Herrmann N, Sketris I, Magin PJ, et al. Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary. Med J Aust 2019;210(4):174–9. https://www.ncbi.nlm.nih.gov/pubmed/30771226
Reeve E, Hilmer S, Chenoweth L, Quirke L, Magin P, Farrell B, et al. Evidence-based clinical practice guidelines for deprescribing cholinesterase inhibitors and memantine. Sydney: The University of Sydney; 2018. http://sydney.edu.au/medicine/cdpc/resources/deprescribing-guidelines.php
Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev 2012;(3):CD006504. https://www.ncbi.nlm.nih.gov/pubmed/22419314
San-Juan-Rodriguez A, Zhang Y, He M, Hernandez I. Association of antidementia therapies with time to skilled nursing facility admission and cardiovascular events among elderly adults with Alzheimer disease. JAMA Netw Open 2019;2(3):e190213. https://www.ncbi.nlm.nih.gov/pubmed/30821828
Stinton C, McKeith I, Taylor JP, Lafortune L, Mioshi E, Mak E, et al. Pharmacological management of lewy body dementia: A systematic review and meta-analysis. Am J Psychiatry 2015;172(8):731–42. https://www.ncbi.nlm.nih.gov/pubmed/26085043
Taylor D, Barnes TRE, Young AH. The Maudsley prescribing guidelines in psychiatry. 13th Oxford: Wiley-Blackwell; 2018. https://www.wiley.com/en-au/The+Maudsley+Prescribing+Guidelines+in+Psychiatry,+13th+Edition-p-9781119442608
Taylor JP, McKeith IG, Burn DJ, Boeve BF, Weintraub D, Bamford C, et al. New evidence on the management of Lewy body dementia. Lancet Neurol 2020;19(2):157–69. https://www.ncbi.nlm.nih.gov/pubmed/31519472